NEWS
- Current Status of Long-acting Growth Hormone Therapies
- Semaglutide vs. Tirzepatide for Obesity
- Click Chemistry Reagents - Azide, Alkyne, DBCO, BCN PEG Products from Biochempeg
- Nectin-4: New Antibody-Drug Conjugate (ADC) Target
- Complement Inhibitors as Therapeutic Agents
- PROTAC Degraders in Clinical Trails: 2025 Update
- Summary of Approved HER2 ADCs on The Market & in Clinical Trials
- FDA Approved PEGylated Drugs By 2025
- Beyond HER3-DXd: New Frontiers in HER3-Targeted Therapies for Lung Cancer
- 2024 FDA Approvals: 50 New Drugs